Xilio Therapeutics Ratios (2024-2025) | XLO

Ratios Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -623.84%-652.32%-790.55%-472.73%-177.71%-10.12%
EBIT Margin -623.84%-652.32%-790.55%-472.73%-177.71%-10.12%
EBITDA Margin -590.79%-619.53%-759.45%-452.73%-195.99%-85.42%
Operating Margin -623.84%-652.32%-790.55%-472.73%-177.71%-10.12%
Net Margin -623.84%-652.32%-790.55%-472.73%-177.71%-10.12%
FCF Margin 846.54%-604.55%-821.52%979.04%-180.70%-91.76%
Efficiency
Assets Average 86.24M82.27M72.87M87.40M118.76M133.75M
Equity Average 29.59M27.20M19.29M14.15M8.88M-0.51M
Invested Capital 25.77M33.42M20.97M17.60M10.70M7.07M-8.10M
Asset Utilization Ratio 0.090.110.130.24
Leverage & Solvency
Equity Ratio 0.310.370.280.250.100.05-0.06
Valuation
Enterprise Value -33.98M-74.95M-61.26M-55.29M-89.10M-121.55M-103.76M
Return Ratios
Return on Sales -6.24%-6.52%-7.91%-4.73%-1.78%-0.10%
Return on Capital Employed -1.43%-0.86%-0.57%
Return on Assets -0.59%-0.65%-0.48%-0.33%
Return on Equity -2.23%-4.02%-6.37%85.33%